SCHEMBL5366575

SCHEMBL5366575

CCOC(=O)C(Cc1ccc(C)c(OC)c1)(NC(C)=O)C(=O)OCC

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.62
RECQL P46063 1/20 0.62
MAPK1 P28482 1/20 0.49
PKM P14618 2/20 0.48
KDM4E B2RXH2 1/20 0.48
THRB P10828 2/20 0.47
ATM Q13315 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPT P10636 2/20 0.46
MEN1 O00255 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HTT P42858 1/20 0.46
PTPRB P23467 2/20 0.45
PTPN2 P17706 1/20 0.40
PTPN1 P18031 1/20 0.40
ACP1 P24666 1/20 0.40
CNR2 P34972 1/20 0.38
TAAR1 Q96RJ0 1/20 0.37
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2688605 0.91 ALDH1A1 (0.64) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL5365516 0.88 ALDH1A1 (0.60) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL5363739 0.88 ALDH1A1 (0.60) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL6132840 0.87 ALDH1A1 (0.68) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL5369771 0.86 ALDH1A1 (0.57) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL11282039 0.85 ALDH1A1 (0.60) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL10278608 0.85 ALDH1A1 (0.56) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL5359731 0.84 ALDH1A1 (0.64) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL5361022 0.82 ALDH1A1 (0.65) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL5361411 0.81 ALDH1A1 (0.64) ALDH1A1RECQLMAPK1PKMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123532-A1 PIPERAZINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2007-05-31 US disclosed
US-7166598-B2 e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases such as asthma, emesis, an anxiety disorder, pollakiuria, urinary incontinence and irritable bowel syndrome ASTELLAS PHARMA INC. (JP) 2007-01-23 US disclosed
EP-1140924-B1 PIPERAZINE DERIVATIVES ASTELLAS PHARMA INC (JP) 2006-03-22 EP disclosed
US-20060014948-A1 e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2006-01-19 US disclosed
EP-1140924-A1 PIPERAZINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-10-10 EP disclosed
WO-2000035915-A1 PIPERAZINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014948-A1 e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals PKD2, TAC3, PKD1 ALDH1A1 2048/4885RECQL 4515/4885MAPK1 837/4885
US-20070123532-A1 PIPERAZINE DERIVATIVES PKD2, SSTR5, IL5 ALDH1A1 1846/4885RECQL 4681/4885MAPK1 991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.